P66. Generating and characterising WT1-specific T cells – research towards adoptive tumour therapy

por Schmied, S, Richter, A, Assenmacher, M
Publicado 2014

Towards a commercial process for the manufacture of genetically modified T cells for therapy

por Kaiser, A D, Assenmacher, M, Schröder, B, Meyer, M, Orentas, R, Bethke, U, Dropulic, B
Publicado 2015

P1184: PHASE I TRIAL OF MB-CART2019.1 IN PATIENTES WITH RELAPSED OR REFRATORY B-CELL NON-HODGKIN LYMPHOMA: 2 YEAR FOLLOW-UP REPORT

por Borchmann, P., Lohneis, A., Gödel, P., Balke-Want, H., Schmid, C., Ayuk, F., Holtkamp, S., Hanssens, L., Zadoyan, G., Friedrichs, B., Assenmacher, M., Bürger, I., Schneider, D., Overstijns, T., Scheid, C., Holtick, U., Miltenyi, S., Hallek, M.
Publicado 2022

PB2115: TRIAL IN PROGRESS: A RANDOMIZED PHASE II STUDY OF MB-CART2019.1 COMPARED TO STANDARD OF CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL INELIGIBLE FOR AUTOLOGOUS ST...

por Borchmann, P., Vandenberghe, P., Urbano, A., Haioun, C., Lemonnier, F., Griškevicius, L., Maury, S., Holtkamp, S., Friedrichs, B., Zadoyan, G., Hanssens, L., Brillant, C., Bethke, U., Assenmacher, M., Bürger, I., Philippe, B., Overstijns, T., Jäger, U., Kersten, M. J.
Publicado 2022